Literature DB >> 17919976

The peripheral-blood transcriptome: new insights into disease and risk assessment.

Steve Mohr1, Choong-Chin Liew.   

Abstract

Future personalized medicine strategies for assessing an individual's health require, ideally, a noninvasive system that is capable of integrating numerous interactive factors, including gender, age, genetics, behavior, environment and comorbidities. Several microarray-based methods developed to meet this goal are currently under investigation. However, most rely on tissue biopsies, which are not readily available or accessible. As an alternative, several recent studies have investigated the use of human peripheral blood cells as surrogate biopsy material. Such studies are based on the assumption that molecular profiling of circulating blood might reflect physiological and pathological events occurring in different tissues of the body. This has led to the development of novel methods for identifying and monitoring blood biomarkers to probe an individual's health status. Here, we discuss the rationale and clinical potential of profiling the peripheral-blood transcriptome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919976     DOI: 10.1016/j.molmed.2007.08.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  121 in total

1.  Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers.

Authors:  Tiffany A Wallace; Ronan F Downey; Caleb J Seufert; Aaron Schetter; Tiffany H Dorsey; Carol A Johnson; Radoslav Goldman; Christopher A Loffredo; Peisha Yan; Francis J Sullivan; Francis J Giles; Feng Wang-Johanning; Stefan Ambs; Sharon A Glynn
Journal:  Carcinogenesis       Date:  2014-05-23       Impact factor: 4.944

Review 2.  Use of transcriptomics in understanding mechanisms of drug-induced toxicity.

Authors:  Yuxia Cui; Richard S Paules
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

Review 3.  Use of peripheral blood transcriptome biomarkers for epilepsy prediction.

Authors:  Stanislav L Karsten; Lili C Kudo; Anatol J Bragin
Journal:  Neurosci Lett       Date:  2011-03-17       Impact factor: 3.046

4.  The effect of colonoscopy on whole blood gene expression profile: an experimental investigation for colorectal cancer biomarker discovery.

Authors:  Ye Xu; Qinghua Xu; Li Yang; Fang Liu; Xun Ye; Fei Wu; Shujuan Ni; Cong Tan; Guoxiang Cai; Xia Meng; Sanjun Cai; Xiang Du
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-12       Impact factor: 4.553

Review 5.  Toxicogenomic profiling of chemically exposed humans in risk assessment.

Authors:  Cliona M McHale; Luoping Zhang; Alan E Hubbard; Martyn T Smith
Journal:  Mutat Res       Date:  2010-04-09       Impact factor: 2.433

6.  To What Extent is Blood a Reasonable Surrogate for Brain in Gene Expression Studies: Estimation from Mouse Hippocampus and Spleen.

Authors:  Matthew N Davies; Sarah Lawn; Steven Whatley; Cathy Fernandes; Robert W Williams; Leonard C Schalkwyk
Journal:  Front Neurosci       Date:  2009-10-09       Impact factor: 4.677

7.  The effects of globin on microarray-based gene expression analysis of mouse blood.

Authors:  Mary E Winn; Matthew A Zapala; Iiris Hovatta; Victoria B Risbrough; Elizabeth Lillie; Nicholas J Schork
Journal:  Mamm Genome       Date:  2010-05-16       Impact factor: 2.957

8.  cDNA targets improve whole blood gene expression profiling and enhance detection of pharmocodynamic biomarkers: a quantitative platform analysis.

Authors:  Mark L Parrish; Chris Wright; Yarek Rivers; David Argilla; Heather Collins; Brendan Leeson; Andrey Loboda; Michael Nebozhyn; Matthew J Marton; Serguei Lejnine
Journal:  J Transl Med       Date:  2010-09-25       Impact factor: 5.531

Review 9.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

10.  An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis.

Authors:  Antonio Julià; Alba Erra; Carles Palacio; Carlos Tomas; Xavier Sans; Pere Barceló; Sara Marsal
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.